Introduction
============

As a type of tumor derived from glial cells in the spine or brain ([@b1-mmr-16-05-6580]), gliomas account for \~80% of malignant brain tumors, and 30% of central nervous system and brain tumors ([@b2-mmr-16-05-6580]). According to their histological features, gliomas are classified into astrocytomas, ependymomas, oligodendrogliomas, optic nerve gliomas, mixed gliomas and brainstem gliomas, among which astrocytomas are the common type of primary brain tumor among adults ([@b3-mmr-16-05-6580]). Gliomas are also divided into low-grade gliomas (grade I and II) and high-grade gliomas (grade III and IV) according to the World Health Organization classification criteria ([@b4-mmr-16-05-6580]). High grade gliomas are malignant gliomas comprising glioblastoma multiforme and anaplastic astrocytomas, and the median overall survival rates of patients with glioblastoma multiforme and anaplastic astrocytomas are \~15 months and 3 years, respectively ([@b5-mmr-16-05-6580]). Therefore, elucidation of the mechanisms underlying malignant gliomas and the development of novel therapeutic strategies are urgently required.

Several studies have investigated the genes in involved in gliomas. In children with malignant gliomas, the overexpression of *p53* is closely associated with adverse outcomes, independently of histological findings and clinical prognostic factors ([@b6-mmr-16-05-6580],[@b7-mmr-16-05-6580]). As a critical mediator of the unfolded protein response, 78-kDa glucose-regulated protein (*GRP78*) is significantly upregulated in human malignant glioma and associated with its proliferation rate, suggesting that drugs capable of inhibiting *GRP78* may be applied in the treatment of malignant glioma ([@b8-mmr-16-05-6580]). Promoter methylation-induced silencing of the O6-methylguanine-DNA methyltransferase DNA-repair gene contributes to longer survival rates in patients with glioblastoma who are treated with alkylating agents ([@b9-mmr-16-05-6580]). A previous study demonstrated that the increased level of hypoxia-inducible factor-1α (*HIF-1α*) is critical for the activation of glioma cell motility through affecting molecules associated with invasion ([@b10-mmr-16-05-6580],[@b11-mmr-16-05-6580]). The Decoy receptor 3 (DcR3) soluble protein may be implicated in the immune evasion and progression of malignant gliomas through inhibiting CD95 ligand (*CD95 L*) ([@b12-mmr-16-05-6580]). It has also been reported that the overexpression of Neuropilin 1 (*NRP1*) promotes tumor progression and is associated with poor prognosis in glioma ([@b13-mmr-16-05-6580]). Spy1, which belongs to the Speedy/RINGO family, is correlated with the poor prognosis in patients with glioma and may serve as an independent prognostic predictor for patients with the disease ([@b14-mmr-16-05-6580]). However, a comprehensive understanding of the mechanisms underlying gliomas is required.

In 2014, Guan *et al* used newly sequenced glioma datasets and downloaded glioma gene expression profiles to investigate the association between known molecular subtypes of grade IV glioblastoma (GBM) with grade II/III gliomas (GII/III), and found shared patterns between the GBMs and GII/IIIs ([@b15-mmr-16-05-6580]). Using the data deposited by Guan *et al* ([@b15-mmr-16-05-6580]), the present study further identified the differentially expressed genes (DEGs) in three comparison groups (grade III, vs. grade II, grade IV, vs. grade II, and grade IV, vs. grade III), and their functions were predicted using enrichment analysis. Subsequently, protein-protein interaction (PPI) networks were constructed and module analysis was performed to analyze the interactions among the DEGs. In addition, glioma-associated genes and glioma marker genes among the DEGs were screened to identify the key genes implicated in malignant glioma.

Materials and methods
=====================

### Microarray data

The gene expression profile of GSE54004, which was sequenced on the platform of GPL18281 Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip (gene symbol version), was downloaded from the Gene Expression Omnibus database (<http://www.ncbi.nih.gov/geo>). To identify the key genes involved in the progression of malignant glioma, a total 143 samples were selected from the GSE54004 dataset, including 12 grade II astrocytomas, 33 grade III astrocytomas and 98 grade IV astrocytomas. The astrocytomas were collected from patients with glioma, following which the tissues were fixed in formalin and embedded in paraffin at MD Anderson Cancer Center (Houston, TX, USA) ([@b15-mmr-16-05-6580]). The GSE54004 dataset was deposited by Guan *et al* ([@b15-mmr-16-05-6580]), and this study by Guan *et al* ([@b15-mmr-16-05-6580]) was approved by the Institutional Review Board of MD Anderson Cancer Center, with informed consent provided by all participants.

### DEG screening

The downloaded gene expression files were merged to obtain a gene expression matrix. Using the Limma package ([@b16-mmr-16-05-6580]) in R (version 3.22.7, <http://www.bioconductor.org/packages/release/bioc/html/limma.html>), the DEGs in three comparison groups (grade III, vs. grade II, grade IV, vs. grade II, and grade IV, vs. grade III) were analyzed. The thresholds of P\<0.05 and \|log~2~fold change (FC)\|≥1 were used. VennPlex software (version 1.0.0.2; <http://www.irp.nia.nih.gov/bioinformatics/vennplex.html>) enables the screening of upregulated, downregulated or contraregulated individual factors between complex data sets ([@b17-mmr-16-05-6580]). Venn diagram analysis was performed for the DEGs screened from different groups using VennPlex software ([@b17-mmr-16-05-6580]) (version 1.0.0.2; <http://www.irp.nia.nih.gov/bioinformatics/vennplex.html>).

### Functional and pathway enrichment analysis

Gene Ontology (GO; <http://www.geneontology.org/>) can be utilized to predict the potential functions for genes and their products in terms of molecular function (MF), cellular component (CC) and biological process (BP) ([@b18-mmr-16-05-6580]). The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) database contains integrated knowledge of information regarding biochemical reactions and compounds, information on proteins and genes, and information on molecular interaction networks ([@b19-mmr-16-05-6580]). GO functional and KEGG pathway enrichment analyses were performed separately for the upregulated and downregulated genes in each comparison group, using Database for Annotation, Visualization and Integrated Discovery software (DAVID version 6.7; <http://www.david.niaid.nih.gov>). Those terms involving at least two genes and with a P-value of P\<0.05 were selected.

### PPI network and module analyses

The Search Tool for the Retrieval of Interacting Genes (STRING version 10.0; <http://string-db.org/>) web resource and database contributes to the identification of PPIs, involving functional and physical associations ([@b20-mmr-16-05-6580]). The PPI associations among the DEGs in each comparison group were searched using the STRING database ([@b21-mmr-16-05-6580]), with a combined score (required confidence) \>0.9. Following this, the PPI networks for the DEGs in each comparison group were visualized separately using Cytoscape software (version 3.2.0; <http://www.cytoscape.org/>) ([@b22-mmr-16-05-6580]). In the PPI network, the degrees of nodes were determined by the number of edges involved, and nodes with higher degrees were determined as key nodes. Module analysis was also performed for the PPI networks using the ClusterONE tool ([@b23-mmr-16-05-6580]).

### Identification of glioma-associated genes and glioma marker genes

The Comparative Toxicogenomics Database (CTD; <http://ctdbase.org/>) ([@b24-mmr-16-05-6580]) collects gene-disease, chemical-disease and chemical-gene interactions, which are manually searched from scientific literature through strict text mining using structured notation, ontologies and controlled vocabularies. Combined with the CTD database, glioma-associated genes and glioma marker genes among the DEGs screened for each group were analyzed.

Results
=======

### DEG analysis

With the thresholds of P\<0.05 and \|log~2~FC\| ≥1, the DEGs in the three comparison groups were analyzed. Compared with grade II samples, a total of 27 DEGs (grade III, vs. grade II), including nine upregulated and 18 downregulated genes, were screened in the grade III samples. A total of 1,446 DEGs (grade IV, vs. grade II), including 643 upregulated and 803 downregulated genes, were identified in the grade IV samples. A total of 776 DEGs (grade IV, vs. grade III), including 410 upregulated and 366 downregulated genes, were identified in the grade IV samples relative to the grade III samples. There were more DEGs in the grade III and grade IV samples.

Venn diagram analysis showed that 20 DEGs, including five upregulated and 15 downregulated genes, were common genes between the grade III, vs. grade II and grade IV, vs. grade II comparison groups. In addition, 698 DEGs, including 356 upregulated and 342 downregulated genes, were common genes between the grade IV, vs. grade II, and grade IV, vs. grade III comparison groups ([Fig. 1](#f1-mmr-16-05-6580){ref-type="fig"}).

### Functional and pathway enrichment analysis

No functions were enriched for the upregulated genes in the grade III, vs. grade II group. However, the downregulated genes in the grade III, vs. grade II group were significantly enriched in functions including synaptic transmission (GO_BP; P=8.06E-04) and plasma membrane (GO_CC; P=1.98E-02; [Table I](#tI-mmr-16-05-6580){ref-type="table"}). No pathways were enriched for the DEGs in the grade III, vs. grade II group.

For the upregulated genes in the grade IV, vs. grade II group, functions including extracellular matrix organization (GO_BP; P=2.64E-17), extracellular matrix (GO_CC; P=2.90E-25), which involves matrix metallopeptidase 9 (*MMP9*) and extracellular matrix structural constituent (GO_MF; P=4.83E-10), in addition to the systemic lupus erythematosus pathway (P=4.70E-16), were significantly enriched. For the downregulated genes in the grade IV, vs. grade II group, functions including transmission of nerve impulse (GO_BP; P=1.12E-20), synapse (GO_CC; P=1.96E-21) and ion channel activity (GO_MF; P=1.35E-18), in addition to the neuroactive ligand-receptor interaction pathway (P=6.62E-07), were significantly enriched ([Table II](#tII-mmr-16-05-6580){ref-type="table"}).

For the upregulated genes in the grade IV, vs. grade III group, terms including extracellular matrix organization (GO_BP; P=9.69E-20), extracellular region part (GO_CC; P=5.11E-28), extracellular matrix structural constituent (GO_MF; P=3.47E-13), which involves chitinase 3-like 1 (*CHI3L1*), and ECM-receptor interaction (P=1.35E-10) were significantly enriched. For the downregulated genes in the grade IV, vs. grade III group, terms including transmission of nerve impulse (GO_BP; P=1.02E-14), synapse (GO_CC; P=4.37E-22), calcium ion binding (GO_MF; P=2.79E-13) and calcium signaling pathway (P=2.15E-05) were significantly enriched ([Table III](#tIII-mmr-16-05-6580){ref-type="table"}).

### PPI network and module analyses

The PPI network constructed for the DEGs in the grade IV, vs. grade II group had 489 nodes and 1,244 interactions ([Fig. 2](#f2-mmr-16-05-6580){ref-type="fig"}), in which four significant modules were identified ([Fig. 3](#f3-mmr-16-05-6580){ref-type="fig"}). The PPI network constructed for the DEGs in the grade IV, vs. grade III group had 243 nodes and 500 interactions ([Fig. 4](#f4-mmr-16-05-6580){ref-type="fig"}), from which two significant modules were identified ([Fig. 5](#f5-mmr-16-05-6580){ref-type="fig"}). The nodes with higher degrees, including MMP9, vascular endothelial growth factor A (VEGFA) and annexin A1 (ANXA1), in the two networks are listed in [Table IV](#tIV-mmr-16-05-6580){ref-type="table"}. MMP9 interacted with VEGFA in these two PPI networks. No PPI network was constructed for the DEGs in grade III, vs. grade II group. The pathways enriched for the genes involved in the modules are shown in [Fig. 6](#f6-mmr-16-05-6580){ref-type="fig"}.

### Identification of glioma-associated genes and glioma marker genes

The glioma-associated genes and glioma marker genes among the DEGs screened for each group were further analyzed using the CTD database. In general, 81.48, 86.93 and 89.95% of the DEGs in the grade III, vs. grade II, grade IV, vs. grade II, and grade IV, vs. grade III comparison groups, respectively, were glioma-associated genes. Of note, there were 10 common glioma marker genes, including *MMP9*, *CHI3L1*, *VEGFA* and S100 calcium binding protein A4 (*S100A4*) between the grade IV, vs. grade II, and grade IV, vs. grade III comparison groups ([Table V](#tV-mmr-16-05-6580){ref-type="table"}).

Discussion
==========

In the present study, a total of 27 (nine upregulated and 18 downregulated), 1,446 (643 upregulated and 803 downregulated) and 776 (410 upregulated and 366 downregulated) DEGs were identified in the grade III, vs. grade II, grade IV, vs. grade II, and grade IV, vs. grade III comparison groups, respectively. Venn diagram analysis showed that 20 DEGs, including five upregulated and 15 downregulated genes, were common genes between the grade III, vs. grade II and grade IV, vs. grade II comparison groups. A total of 698 DEGs, including 356 upregulated and 342 downregulated genes) were common genes between the grade IV, vs. grade II and grade IV, vs. grade III comparison groups. Four significantly modules were identified from the PPI network constructed for the DEGs in the grade IV, vs. grade II group, and two significantly modules were identified from the PPI network constructed for the DEGs in the grade IV, vs. grade III group. No PPI network was constructed for the DEGs in the grade III, vs. grade II group. It was found that 81.48, 86.93 and 89.95% of the DEGs in the grade III, vs. grade II, grade IV vs. grade II, and grade IV vs. grade III comparison groups, respectively, were glioma-associated genes. In addition, there were 10 common glioma marker genes, including *MMP9*, *CHI3L1*, *VEGFA* and *S100A4*, between the grade IV, vs. grade II and grade IV, vs. grade III comparison groups.

Inhibiting the expression of *MMP9* through RNA interference represses the malignancy of glioma cells, indicating that it can be applied in the treatment of malignant gliomas ([@b25-mmr-16-05-6580]--[@b27-mmr-16-05-6580]). *MMP2* and *MMP9* have significant effects on the degradation of extracellular matrix (ECM) and angiogenesis, and on the invasiveness of gliomas, therefore, they can be utilized in targeted therapy of malignant glioma ([@b28-mmr-16-05-6580]). *CHI3L1* and *MMP-9* are overexpressed in malignant gliomas, and can serve as a predictors of survival rates in patients with the disease ([@b29-mmr-16-05-6580]). In addition, *CHI3L1* is important in regulating local invasiveness and malignant transformation in gliomas, therefore, *CHI3L1* may be a used as a molecular target in the treatment of gliomas ([@b30-mmr-16-05-6580]). In patients with glioma, the serum level of CHI3L1, which encodes a secreted glycoprotein, is associated with tumor grade and possibly tumor burden in glioblastoma multiforme ([@b31-mmr-16-05-6580]). Functional enrichment analyses have shown that *MMP9* and *CHI3L1* were separately enriched in the ECM and its structural constituent, respectively. ECM rigidity can mediate the invasion of glioblastoma multiforme cells through actomyosin contractility ([@b32-mmr-16-05-6580],[@b33-mmr-16-05-6580]). These findings indicate that *MMP9* and *CHI3L1* may function in the progression of malignant gliomas through the ECM.

*VEGF* is an effective mediator of vascular permeability, and its inhibition can decrease tumor burden and edema production in malignant glioma ([@b34-mmr-16-05-6580]). The growth and progression of astrocytoma is dependent on neovascularization, and the angiogenesis factor *VEGFA* may be essential for the infiltrative and aggressive growth of astrocytomas ([@b35-mmr-16-05-6580]). *VEGFA* affects the neovascularization and invasion of glioblastoma, not only by promoting endothelial mitogenesis and permeability, but also by regulating *MMP2* ([@b36-mmr-16-05-6580]). In the two PPI networks in the present study, VEGFA interacted with MMP9, indicating that *VEGFA* may also affect malignant gliomas via interacting with *MMP9*.

The expression of *S100A4* is promoted by neutrophil infiltration, and targeting *S100A4* may be promising in reducing antiangiogenic therapy resistance and inhibiting the glioma malignant phenotype ([@b37-mmr-16-05-6580]). *S100A4/Mts1* has a higher expression in high-grade glioblastomas, compared with low-grade astrocytic tumors, indicating that it has an effect on brain tumor progression ([@b38-mmr-16-05-6580]). *ANXA1*, targeted by forkhead box M1 (*FOXM1*) has a high expression in gliomas and can function as a predictor of poor prognosis in patients with the disease ([@b39-mmr-16-05-6580]). A previous study demonstrated that *ANXA1* may contribute to maintaining brain homeostasis and may be used as chemotherapeutic target in the treatment of glioblastoma multiforme ([@b40-mmr-16-05-6580]). Therefore, *S100A4* and *ANXA1* may be involved in the development of malignant gliomas.

In conclusion, the present study identified 27, 1,446 and 776 DEGs in the grade III, vs. grade II, grade IV, vs. grade II, and grade IV vs. grade III comparison groups respectively. It was found that *MMP9*, *CHI3L1*, *VEGFA*, *S100A4* and *ANXA1* may act in the progression of malignant gliomas. However, these findings were obtained from bioinformatics analysis and require further validation.
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###### 

Functions enriched for the downregulated genes in the grade III, vs. grade II group.

  Category   Term                                               P-value    Genes (n)   Gene symbol
  ---------- -------------------------------------------------- ---------- ----------- ------------------------------------------------------------
  BP         GO:0007268\~synaptic transmission                  8.06E-04   4           *NOS1, PCDHB4, UNC13C, HTR2A*
             GO:0019226\~transmission of nerve impulse          1.28E-03   4           *NOS1, PCDHB4, UNC13C, HTR2A*
             GO:0050877\~neurological system process            5.56E-03   5           *NOS1, PCDHB4, POU4F1, UNC13C, HTR2A*
             GO:0007267\~cell-cell signaling                    5.97E-03   4           *NOS1, PCDHB4, UNC13C, HTR2A*
             GO:0043271\~negative regulation of ion transport   1.52E-02   2           *NOS1, HTR2A*
             GO:0007416\~synaptogenesis                         2.11E-02   2           *PCDHB4, POU4F1*
             GO:0009408\~response to heat                       3.67E-02   2           *NOS1, XYLT1*
             GO:0050808\~synapse organization                   3.99E-02   2           *PCDHB4, POU4F1*
  CC         GO:0005886\~plasma membrane                        1.98E-02   8           *CAMKV, EPHB6, NOS1, PCDHB4, UNC13C, TMEM25, ABCC8, HTR2A*

GO, Gene Ontology; BP, biological process; CC, cellular component.

###### 

Functions and pathways separately enriched for the upregulated and downregulated genes in the grade IV, vs. grade II group.

  Category        Term                                                      P-value    Genes (n)   Gene symbol
  --------------- --------------------------------------------------------- ---------- ----------- -----------------------------------------------------------------------------------------------
  Upregulated                                                                                      
  BP              GO:0030198\~extracellular matrix organization             2.64E-17   29          *ADAMTS14, MMP9, LUM, COL3A1, ELN, POSTN, DCN, SERPINH1, TGFB2, TNFRSF11B...*
                  GO:0009611\~response to wounding                          2.31E-15   61          *F2RL2, NRP1, S100A8, S100A9, C1QC, CXCL10, TGFB2, CD97, S1PR3, SAA2...*
                  GO:0022403\~cell cycle phase                              2.89E-15   53          *KIF23, KIFC1, PRC1, PTTG1, GTSE1, CDKN2C, CDCA2, DNAJC2, CCNA2, SNHG3-RCC1...*
  CC              GO:0031012\~extracellular matrix                          2.90E-25   62          *CTHRC1, LTBP1, NPNT, MMP9, MMP7, POSTN, MMP2, TGFB2, TNFRSF11B, TGFBI...*
                  GO:0005576\~extracellular region                          1.42E-23   161         *F2RL2, CTHRC1, LTBP1, C9ORF47, FAM20A, MMP9, FAM20C, MMP7, TNFSF14, POSTN...*
                  GO:0005578\~proteinaceous extracellular matrix            5.13E-23   57          *CTHRC1, LTBP1, NPNT, MMP9, MMP7, POSTN, MMP2, TNFRSF11B, TGFBI, LOX...*
  MF              GO:0005201\~extracellular matrix structural constituent   4.83E-10   19          *COL4A2, COL4A1, LUM, ELN, COL3A1, CHI3L1, MGP, COL5A3, EMILIN2, COL5A2...*
                  GO:0050840\~extracellular matrix binding                  5.02E-10   12          *BGN, TGFBI, C6ORF15, VEGFA, ELN, OLFML2A, NID1, DCN, THBS1, ADAM9...*
                  GO:0030246\~carbohydrate binding                          1.18E-09   38          *CCL2, C21ORF63, CD248, SUSD2, HEXB, POSTN, DCN, MDK, SIGLEC9, HMMR...*
  Pathway         hsa05322: Systemic lupus erythematosus                    4.70E-16   28          *HIST1H2AB, HIST4H4, HIST1H4L, HIST2H2AA4, HLA-DRB1, C1R, C1S, C1QC, HIST1H2BO, HIST1H2BM...*
                  hsa04512: ECM-receptor interaction                        6.20E-11   21          *COL4A2, COL4A1, TNC, COL3A1, ITGA1, HSPG2, ITGA3, COL5A3, COL5A2, COL5A1...*
                  hsa04510: Focal adhesion                                  5.34E-09   29          *CAV2, CAV1, TNC, COL3A1, COL6A3, COL6A1, ZYX, PDGFD, LAMB1, THBS1...*
  Downregulated                                                                                    
  BP              GO:0019226\~transmission of nerve impulse                 1.12E-20   58          *SYT1, GABRB3, SYT4, GLRA3, CNP, GABBR2, KCNIP2, VIPR1, SLC1A4, KCNQ5...*
                  GO:0007268\~synaptic transmission                         1.47E-19   52          *SYT1, GABRB3, SYT4, GLRA3, CNP, GABBR2, KCNIP2, VIPR1, SLC1A4, KCNQ5...*
                  GO:0006811\~ion transport                                 2.91E-15   79          *KCNC2, KCNH1, SLC22A17, SLC8A3, JPH4, JPH3, GABRB3, SCN3A, KCNAB1, SCN3B...*
  CC              GO:0045202\~synapse                                       1.96E-21   63          *SYT1, SEPT3, ENAH, CLSTN2, GABRB3, SYT4, GRIP1, GLRA3, GABRB1, SYT9...*
                  GO:0044456\~synapse part                                  7.63E-19   49          *SYT1, SYT4, GABRB3, CLSTN2, GRIP1, GABRB1, GLRA3, SYT9, GABBR2, GRIN3A...*
                  GO:0043005\~neuron projection                             2.24E-12   48          *SNCG, SYT1, CDK5R1, CCK, ADCY2, SYT4, GABRB3, SNCB, ALDOC, GRIN3A...*
  MF              GO:0005216\~ion channel activity                          1.35E-18   59          *KCNC2, KCNH1, SCN3A, GABRB3, KCNAB1, SCN3B, GLRA3, GABRB1, GRIN3A, KCNIP2...*
                  GO:0015267\~channel activity                              1.56E-18   61          *KCNC2, KCNH1, SCN3A, GABRB3, KCNAB1, SCN3B, GLRA3, GABRB1, GRIN3A, KCNIP2...*
                  GO:0022803\~passive transmembrane transporter activity    1.76E-18   61          *KCNC2, KCNH1, SCN3A, GABRB3, KCNAB1, SCN3B, GLRA3, GABRB1, GRIN3A, KCNIP2...*
  Pathway         hsa04080: Neuroactive ligand-receptor interaction         6.62E-07   28          *GPR83, THRA, PRLHR, GABRB3, GABRB1, DRD5, GLRA3, GRIN3A, GABBR2, VIPR1...*
                  hsa04020: Calcium signaling pathway                       6.83E-06   21          *SLC8A3, ADCY2, SLC8A2, NOS1, ADCY8, DRD5, GRIN1, CACNA1I, GRM1, ATP2B2...*
                  hsa04360: Axon guidance                                   2.96E-03   13          *NGEF, PLXNB1, ABLIM3, NTN4, SLIT1, EPHB1, PAK7, EPHB6, SEMA6B, EPHA6...*

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Functions and pathways separately enriched for the upregulated and downregulated genes in the grade IV, vs. grade III group.

  Category        Term                                                      P-value    Genes (n)   Gene symbol
  --------------- --------------------------------------------------------- ---------- ----------- -------------------------------------------------------------------------------------------
  Upregulated                                                                                      
  BP              GO:0030198\~extracellular matrix organization             9.69E-20   27          *IBSP, ADAMTS14, LUM, MMP9, COL3A1, POSTN, SERPINH1, TGFBI, BCL3, LOX...*
                  GO:0001944\~vasculature development                       1.06E-15   34          *CAV1, NRP1, TNFRSF12A, COL3A1, ENPEP, TYMP, ACE, HOXA3, ANG, HMOX1...*
                  GO:0043062\~extracellular structure organization          1.42E-15   28          *IBSP, ADAMTS14, MMP9, LUM, COL3A1, POSTN, SERPINH1, TGFBI, BCL3, LOX...*
  CC              GO:0044421\~extracellular region part                     5.11E-28   87          *CTHRC1, MMP9, IGFBP6, MMP7, TNFSF14, POSTN, HP, CXCL10, ISG15, SAA2...*
                  GO:0031012\~extracellular matrix                          3.40E-26   52          *CTHRC1, MMP9, MMP7, POSTN, ANG, TGFBI, LOX, SPON2, VWA1, LOXL1...*
                  GO:0005578\~proteinaceous extracellular matrix            6.96E-26   50          *ADAMTS18, CTHRC1, ADAMTS14, CD248, MMP9, LUM, COL3A1, MMP7, POSTN, TIMP1...*
  MF              GO:0005201\~extracellular matrix structural constituent   3.47E-13   19          *COL18A1, COL4A2, COL4A1, LUM, EFEMP2, COL3A1, CHI3L1, MGP, EMILIN2, COL5A2...*
                  GO:0019838\~growth factor binding                         1.25E-11   19          *COL4A1, IL2RA, OSMR, IGFBP6, COL3A1, ESM1, COL5A1, CD36, IL1RAP, COL1A2...*
                  GO:0030247\~polysaccharide binding                        7.81E-09   19          *FGFR1, SUSD2, C6ORF15, POSTN, CXCL6, COL5A1, PCOLCE2, TNFAIP6, BGN, ANG...*
  Pathway         hsa04512: ECM-receptor interaction                        1.35E-10   17          *IBSP, COL4A2, COL4A1, COL3A1, ITGA1, ITGA3, COL5A2, COL5A1, CD36, ITGA5...*
                  hsa04510: Focal adhesion                                  2.82E-09   23          *IBSP, CAV2, CAV1, COL4A2, COL4A1, VAV3, COL3A1, MET, ITGA1, ACTN1...*
                  hsa05322: Systemic lupus erythematosus                    2.98E-05   12          *HIST1H2AB, HIST2H3A, HIST2H2AA4, HIST1H4L, HIST1H2BH, ACTN1, C1R, HIST2H3C, HIST2H3D...*
  Downregulated                                                                                    
  BP              GO:0019226\~transmission of nerve impulse                 1.02E-14   34          *SYT1, SYT4, GABRB3, GLRA3, GABBR2, KCNIP2, SLC1A4, NPTX1, GAD2, S1PR1...*
                  GO:0007268\~synaptic transmission                         2.14E-13   30          *SYT1, SYT4, GABRB3, GLRA3, GABBR2, KCNIP2, SLC1A4, NPTX1, GAD2, SYN1...*
                  GO:0007267\~cell-cell signaling                           5.65E-12   40          *SYT1, EDN3, CCL3, SYT4, GABRB3, FGF17, CAMK2G, GLRA3, FGF12, GABBR2...*
  CC              GO:0045202\~synapse                                       4.37E-22   45          *SYT1, SEPT3, CDK5R1, ENAH, SNAP91, CLSTN2, GABRB3, SYT4, GLRA3, GABRB1...*
                  GO:0044456\~synapse part                                  1.31E-20   37          *SYT1, SNAP91, CLSTN2, GABRB3, SYT4, GABRB1, GLRA3, SYT9, BCAN, ATP6V1G2...*
                  GO:0043005\~neuron projection                             2.66E-11   31          *SNCG, SYT1, CDK5R1, CCK, ADCY2, SNCB, SYT4, GABRB3, GRIN3A, GABBR2...*
  MF              GO:0005509\~calcium ion binding                           2.79E-13   53          *SYT1, CLSTN2, SYT4, MASP1, SYT9, GRIN3A, KCNIP2, KCNIP3, SYP, ATP2B2......*
                  GO:0022836\~gated channel activity                        4.21E-12   29          *KCNC2, GABRB3, GABRB1, GLRA3, GRIN3A, KCNIP2, KCNK12, KCNJ3, KCNIP3, GRIN2C......*
                  GO:0005216\~ion channel activity                          3.09E-11   31          *KCNC2, GABRB3, GABRB1, GLRA3, GRIN3A, KCNIP2, KCNK12, KCNJ3, KCNIP3, SLC1A4......*
  Pathway         hsa04080: Neuroactive ligand-receptor interaction         9.42E-07   19          *GABRG2, GABRA1, THRA, PRLHR, GABRB3, GLRA3, GABRB1, ADCYAP1R1, GRIN1, GRIN3A......*
                  hsa04020: Calcium signaling pathway                       2.15E-05   14          *ADCY2, SLC8A2, ADCY8, CAMK2G, CACNA1I, GRIN1, GRM1, ATP2B2, CD38, GRIN2C......*
                  hsa04720: Long-term potentiation                          1.65E-03     7         *GRIA2, ADCY8, GRIN2C, CAMK2G, PPP1R1A, GRIN1, GRM1*

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Top 15 nodes with highest degrees in the grade IV, vs. grade II protein-protein interaction networks.

  Node      Log fold change   Degree
  --------- ----------------- --------
  ADCY2     −1.98963          26
  ADCY8     −1.17088          26
  BIRC5     1.359254          26
  CDC20     1.816218          26
  CENPA     1.236634          24
  CDK2      1.239547          24
  GPR17     −1.2297           23
  ANXA1     2.129899          23
  ZWINT     1.196125          23
  IL8       1.634318          22
  MMP9      3.458891          22
  VEGFA     2.236317          22
  CLASP2    −1.04519          21
  CCNB1     1.290933          21
  MAD2L1    1.046268          20
  VEGFA     2.225246          19
  COL18A1   1.107411          18
  BIRC5     1.006404          16
  ADCY8     −1.09838          16
  ADCY2     −1.40787          16
  CDC20     1.497869          15
  COL4A1    1.877445          15
  COL1A1    2.614414          15
  ANXA1     1.793973          15
  ITGA1     1.174656          15
  MMP9      3.32357           14
  CCNB1     1.097028          14
  IL8       1.420499          14
  COL1A2    2.180694          14
  COL9A3    1.231098          14

###### 

Numbers of glioma-associated genes and glioma marker genes among the differentially expressed genes screened for each group.

  Group                    Glioma-associated genes, n (%)   Glioma marker genes (n)
  ------------------------ -------------------------------- -------------------------
  Grade III vs. grade II   22 (81.48)                         1
  Grade IV vs. grade II    1,257 (86.93)                    24
  Grade IV vs. grade III   698 (89.95)                      13
